ClinicalTrials.gg
RecruitingNCT06241482Updated Mar 4, 2025

Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care

An interventional study of Enhanced recovery after surgery and Conventional therapy in Neurocritical Care, Traumatic Brain Injury and Cerebrovascular Disease, sponsored by Shanghai 6th People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Shanghai 6th People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.

Planned enrollment
15th of 26
80 · median 83
Started
2024
with 13 others
No phase
18 of 60
8 open now
Primary completion
2027-04
later than 19 of 29 live
Registered
36th of 60
by date
Lead sponsor
6 of 60
Shanghai 6th People's Hospital

Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 15th largest by planned enrollment of the 26 interventional ones that give a count, is one of 14 that started in 2024, is one of 18 with no phase, reaches primary completion later than 19 of the 29 other live ones, and was the 36th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Brain Injuries, Traumatic with a site in China, or all of them as a file.
02

Study summary

Enhanced recovery after surgery (ERAS) is a strategy of perioperative management aimed to accelerate the rehabilitation of patients through various optimized perioperative managements as well as ongoing adherence to a patient-focused, multidisciplinary, and multimodal approach. Alleviating the injury and stress caused by surgery or disease is the core principle of ERAS, which has been shown to reduce complication rates after surgery, promote patient recovery, decrease hospital length of stay and reduce costs. ERAS has been widely applied in many surgical perioperative fields, and it has achieved remarkable effects. However, there are few applications of ERAS in neurosurgery, especially in clinical trials of neurocritical care patients.

Therefore, the investigators attempt to conduct the study of ERAS in neurosurgical intensive patients using a series of optimized perioperative managements that have been verified to be effective by evidence-based medicine, and to evaluate the safety and effectiveness of ERAS in neurocritical care. The aim of this study is to explore the most suitable ERAS protocols to accelerate the postoperative rehabilitation process of neurocritical care patients, and to provide more evidence-based medicine for the effectiveness and safety of ERAS in neurosurgery.

03

Conditions studied

  • Neurocritical Care
  • Traumatic Brain Injury
  • Cerebrovascular Disease
  • Moderate or Severe Coma

Keywords

  • Neurocritical Care
  • Traumatic Brain Injury
  • Cerebrovascular Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years old
  • Patients with moderate or severe acute traumatic brain injury or cerebrovascular disease requiring neurosurgical intensive care treatment
  • Hospitalization time ≥ 1 week
  • The guardian is able to understand and actively cooperate in completing the project
  • The guardian signs an form

Exclusion criteria

Exclusion Criteria:

  • Patients undergoing non-surgical treatment
  • Patients diagnosed as brain death within the first 24 hours after admission to NICU
  • Patients undergoing cardiopulmonary resuscitation, maintenance dialysis, end-stage tumors, and disseminated cancer
  • Patients who withdraw treatment during hospitalization or are discharged automatically
  • Patients who underwent unplanned secondary surgery during the research process
  • Individuals who cannot be followed up during the research process
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Enhanced recovery after surgery

    The technologies, processes and measures of enhanced recovery after surgery were applied.

    Procedure: Enhanced recovery after surgery

  • Active comparator
    Conventional therapy

    Conventional therapy were applied.

    Procedure: Conventional therapy

Interventions

  • ProcedureEnhanced recovery after surgery

    The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects: 1. Early assessment and treatment 2. Optimized anesthetic protocol 3. Reducing surgical stress 4. Multi-modal comprehensive monitoring 5. Comprehensive diagnosis and treatment in neurosurgical intensive care 6. Intensive early rehabilitation treatment

  • ProcedureConventional therapy

    Conventional therapy in neurocritical care.

06

What researchers measure

Primary outcomes

  1. Clinical prognosis

    Glasgow Outcome Scale score (1 = death; 2 = persistent vegetative state; 3 = severe disability; 4 = moderate disability; 5 = good but not necessarily complete recovery; unfavorable outcome was defined as score of ≤3, and favorable outcome was defined as a score of \>3)

    Time frame: One month, three and six months after injury or attack

  2. Neurological function assessment

    Modified Rankin scale score (0 = no symptoms; 1 = no significant disability; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = dead; favorable outcome was defined as score of 0-2, and unfavorable outcome was defined as score of 3-6)

    Time frame: One month, three and six months after injury or attack

Secondary outcomes

  1. Neuroimaging evaluation

    Computer tomography or magnetic resonance imaging

    Time frame: One week, two weeks after surgery; one month, three and six months after injury or attack

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 30 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2024
First posted
Feb 5, 2024
StartActual
Oct 15, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06241482
Lead sponsor
Shanghai 6th People's Hospital
Responsible party
Hao Chen, MD, PhD (Associate Professor, Chief Physician, Graduate Supervisor, Shanghai 6th People's Hospital) — Principal investigator
First posted
Feb 5, 2024
Start date
Oct 15, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 4, 2025

Study contacts

Hao Chen, M.D., Ph.D.
Contact
hao.chen@shsmu.edu.cn
8602164369181 ext. 8405
Hao Chen, M.D., Ph.D.
study director · Shanghai 6th Peoples' Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion